JP2019508486A - 胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィcncm i−4573株 - Google Patents
胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィcncm i−4573株 Download PDFInfo
- Publication number
- JP2019508486A JP2019508486A JP2018557200A JP2018557200A JP2019508486A JP 2019508486 A JP2019508486 A JP 2019508486A JP 2018557200 A JP2018557200 A JP 2018557200A JP 2018557200 A JP2018557200 A JP 2018557200A JP 2019508486 A JP2019508486 A JP 2019508486A
- Authority
- JP
- Japan
- Prior art keywords
- bacterial strain
- strain
- composition
- strain according
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 230000002265 prevention Effects 0.000 title claims abstract description 9
- 208000005577 Gastroenteritis Diseases 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 claims abstract description 39
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 44
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 19
- 230000000112 colonic effect Effects 0.000 claims description 7
- 239000002417 nutraceutical Substances 0.000 claims description 7
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 230000001332 colony forming effect Effects 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000002389 Pouchitis Diseases 0.000 claims description 2
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 35
- 206010009887 colitis Diseases 0.000 description 31
- 238000012360 testing method Methods 0.000 description 22
- 230000003110 anti-inflammatory effect Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 102000004890 Interleukin-8 Human genes 0.000 description 14
- 108090001007 Interleukin-8 Proteins 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 229940096397 interleukin-8 Drugs 0.000 description 13
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 13
- 102000003814 Interleukin-10 Human genes 0.000 description 10
- 108090000174 Interleukin-10 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940076144 interleukin-10 Drugs 0.000 description 9
- 229940028885 interleukin-4 Drugs 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 102000003896 Myeloperoxidases Human genes 0.000 description 7
- 108090000235 Myeloperoxidases Proteins 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000012313 Kruskal-Wallis test Methods 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000004921 distal colon Anatomy 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000566600 Podomys Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
F.prausnitziiは、フィルミクテス(Firmicutes)門の主要メンバーであり、健康なヒトの大腸の細菌叢における最も豊富な常在細菌の一つである。
本発明は、生理学的に許容される媒体中に、本発明のフィーカリバクテリウム・プラウスニッツィI−4573株を少なくとも含む組成物にも関する。
I.細菌株及び培養条件
試験したF.prausnitzii株の単離菌は、N2=85%、CO2=10%及びH2=5%を満たした嫌気チャンバー内で、1mg/mlのセロビオース(Sigma−Aldrich Chemie社(スイス、ブフス))、1mg/mlのマルトース(Sigma−Aldrich社)及び0.5mg/mlのシステイン(Sigma−Aldrich社)を添加したYBHI培地(0.5%酵母エキス添加ブレインハートインフュージョン培地)(Difco社(米国デトロイト))中37℃で培養する。
・CNCM I−4573株及びCNCM I−4573株は40歳の男性から単離され、
・A2−165(DSMZ 17677)株は34歳の女性から単離されたものである(Duncan SH et al., IJSEM, 2002, 52(Pt 6):2141−2146)。
A.細胞培養
HT−29細胞株(ATCC HTB−38)(LGC−Standars社)は、10%(w/v)の熱非働化ウシ胎児血清(FBS)(GibcoBRL社(フランス、エラニー))をペニシリンG/ストレプトマイシン(5000IU/ml,5000μg/ml)(Sigma−Aldrich社)と共に添加したダルベッコ改変イーグル培地(DMEM)(Sigma−Aldrich社)中で培養される。培養物は、25cm2の組織培養フラスコ(Nunc社(デンマーク、ロスキレ)中でコンフルエントに達するまで5%(v/v)CO2含有雰囲気中37℃でインキュベートされる。
HT−29を用いた抗炎症試験は、Kechaou他(Applied and environmental microbiology 2012, 79 (5): 1491−1499)に記載された手順に従って行われる。
統計解析は、GraphPadソフトウェア(GraphPad Software社(米国カリフォルニア州ラホヤ))によって実施される。すべてのデータは平均±SEMとして表される。
得られた結果を図1に示す。
A.細胞培養
5人の健康なドナーに由来する市販のPBMC(StemCell Technologies社(フランス))を使用する。
F.prausnitzii菌との共培養アッセイ用のPBMCを調製するため、フラスコを水浴中37℃で融解し、次いで10%熱非働化FCS、1%L−グルタミン及び0.1%ペニシリン/ストレプトアビジンを添加したRPMI−1640培地(培地の成分はLonza社(スイス)から購入)を含む培地に移す。細胞の凝集を防ぐため、DNase(100μg/ml、Roche Applied Science社(フランス))を培地に加えた。
統計解析は、GraphPadソフトウェア(GraphPad Software社(米国カリフォルニア州ラホヤ))によって実施される。すべてのデータは平均±SEMとして表される。
得られた結果を図2に示す。
A.DNBS大腸炎の誘導及び菌投与
DNBS誘導大腸炎プロトコルは既報の通りである(Martin R, et al. Infiamm Bowel Dis. Mars 2014 ; 20(3):417−30)。
マウスを頸椎脱臼により屠殺し、腹腔を開く。結腸及び小腸を取り出し、縦に開き、巨視的損傷について直ちに評価する。
好中球浸潤マーカーとして用いられるミエロペルオキシダーゼ(MPO)活性は、Bradley他(J. Invest. Dermatol. 1982, 78(3):206−209)に記載された方法の変法によってアッセイする。
1cm長の遠位結腸を回収し、組織破砕装置(tissue lyser)において、プロテアーゼ阻害剤(Sigma−Aldrich)を含むTris−HCl緩衝液400μl中でホモジナイズする。
統計解析は、GraphPadソフトウェア(GraphPad Software社(米国カリフォルニア州ラホヤ))によって実施される。
1.図4の巨視的スコアは、I−4573株で処置したDNBSマウスにおいて、大腸炎のない対照マウスで得られたものと同等の、非常に良好なスコアが得られたことを示す。
Claims (13)
- 個体における炎症性胃腸疾患の処置及び/又は予防に使用するための、CNCMに受託番号CNCM I−4573で寄託されたフィーカリバクテリウム・プラウスニッツィ(Faecalibacterium prausnitzii)種の細菌株。
- 個体が哺乳動物である、請求項1に記載の細菌株。
- 個体がヒトである、請求項1又は請求項2に記載の細菌株。
- 炎症性胃腸疾患が炎症性腸疾患である、請求項1乃至請求項3のいずれか1項に記載の細菌株。
- 炎症性胃腸疾患が結腸炎症性腸疾患である、請求項1乃至請求項4のいずれか1項に記載の細菌株。
- 結腸炎症性腸疾患が、クローン病、潰瘍性大腸炎及び回腸嚢炎からなる群から選択される、請求項5に記載の細菌株。
- 結腸炎症性腸疾患が、クローン病及び潰瘍性大腸炎からなる群から選択される、請求項5又は請求項6に記載の細菌株。
- 当該細菌株が、生理学的に許容される媒体を含む組成物中に含まれる、請求項1乃至請求項7のいずれか1項に記載の細菌株。
- 当該細菌株が経口組成物中に含まれる、請求項1乃至請求項8のいずれか1項に記載の細菌株。
- 当該細菌株が栄養補助食品中に含まれる、請求項1乃至請求項9のいずれか1項に記載の細菌株。
- 前記組成物が、薬剤として107〜1011コロニー形成単位(cfu)に相当する1日投与量、好ましくは109cfuの1日投与量の形態での投与に適している、請求項8乃至請求項10のいずれか1項に記載の細菌株。
- 前記組成物が経口投与用のものであり、食品、飲料、医薬品、機能性食品、食品添加物、栄養補助食品及び乳製品からなる群から選択される、請求項8乃至請求項11のいずれか1項に記載の細菌株。
- 前記組成物が経口投与用のものであり、栄養補助食品である、請求項12に記載の細菌株。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1650567 | 2016-01-25 | ||
FR1650567A FR3046934B1 (fr) | 2016-01-25 | 2016-01-25 | Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale |
PCT/EP2017/051306 WO2017129515A1 (fr) | 2016-01-25 | 2017-01-23 | Souche de faecalibacterium prausnitzii cncm 1-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019508486A true JP2019508486A (ja) | 2019-03-28 |
JP2019508486A5 JP2019508486A5 (ja) | 2020-02-13 |
JP6935632B2 JP6935632B2 (ja) | 2021-09-15 |
Family
ID=55862967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018557200A Active JP6935632B2 (ja) | 2016-01-25 | 2017-01-23 | 胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィcncm i−4573株 |
Country Status (18)
Country | Link |
---|---|
US (1) | US10918678B2 (ja) |
EP (1) | EP3407902B1 (ja) |
JP (1) | JP6935632B2 (ja) |
CN (1) | CN109310714A (ja) |
AU (1) | AU2017211244B2 (ja) |
BR (1) | BR112018015121A2 (ja) |
CA (1) | CA3012214A1 (ja) |
ES (1) | ES2820338T3 (ja) |
FR (1) | FR3046934B1 (ja) |
HU (1) | HUE050810T2 (ja) |
IL (1) | IL260752B (ja) |
LT (1) | LT3407902T (ja) |
NZ (1) | NZ744528A (ja) |
PL (1) | PL3407902T3 (ja) |
PT (1) | PT3407902T (ja) |
SG (1) | SG11201806361PA (ja) |
WO (1) | WO2017129515A1 (ja) |
ZA (1) | ZA201805302B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
KR102245415B1 (ko) * | 2020-12-14 | 2021-04-29 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주 배양 배지 조성물 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111107860A (zh) * | 2017-06-16 | 2020-05-05 | 表飞鸣制药株式会社 | 脂肪相关疾病和/或炎症的预防或治疗剂 |
FR3084255B1 (fr) * | 2018-07-26 | 2020-07-03 | Institut National De La Recherche Agronomique (Inra) | Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu |
FR3099053B1 (fr) * | 2019-07-24 | 2023-01-20 | Inst Nat De La Rech Agronomique Inra | Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale |
EP3838276A1 (en) | 2019-12-17 | 2021-06-23 | Exeliom Biosciences | Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation |
CN116529355A (zh) * | 2020-08-14 | 2023-08-01 | Ko生物技术有限公司 | 普氏栖粪杆菌菌株及其用途 |
EP4219681A1 (en) * | 2020-09-28 | 2023-08-02 | CJ Bioscience, Inc. | Composition for diagnosis or treatment of inflammatory diseases, comprising microorganism |
CN112402459B (zh) * | 2020-10-27 | 2023-01-31 | 江南大学 | 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用 |
EP4166150A1 (en) | 2021-10-15 | 2023-04-19 | Exeliom Biosciences | Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2988761A1 (en) * | 2013-03-05 | 2016-03-02 | Rijksuniversiteit Groningen | Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation. |
HUE049340T2 (hu) * | 2014-11-13 | 2020-09-28 | Institut National De La Rech Pour Lagriculture Lalimentation Et Lenvironnement | Faecalibacterium prausnitzii törzsek gasztrointesztinális fájdalom kezelésére és megelõzésére |
-
2016
- 2016-01-25 FR FR1650567A patent/FR3046934B1/fr active Active
-
2017
- 2017-01-23 PT PT177023223T patent/PT3407902T/pt unknown
- 2017-01-23 AU AU2017211244A patent/AU2017211244B2/en active Active
- 2017-01-23 BR BR112018015121-1A patent/BR112018015121A2/pt unknown
- 2017-01-23 NZ NZ744528A patent/NZ744528A/en unknown
- 2017-01-23 HU HUE17702322A patent/HUE050810T2/hu unknown
- 2017-01-23 EP EP17702322.3A patent/EP3407902B1/fr active Active
- 2017-01-23 CN CN201780019735.0A patent/CN109310714A/zh active Pending
- 2017-01-23 WO PCT/EP2017/051306 patent/WO2017129515A1/fr active Application Filing
- 2017-01-23 ES ES17702322T patent/ES2820338T3/es active Active
- 2017-01-23 SG SG11201806361PA patent/SG11201806361PA/en unknown
- 2017-01-23 JP JP2018557200A patent/JP6935632B2/ja active Active
- 2017-01-23 CA CA3012214A patent/CA3012214A1/fr active Pending
- 2017-01-23 PL PL17702322T patent/PL3407902T3/pl unknown
- 2017-01-23 LT LTEP17702322.3T patent/LT3407902T/lt unknown
- 2017-01-23 US US16/072,319 patent/US10918678B2/en active Active
-
2018
- 2018-07-24 IL IL260752A patent/IL260752B/en active IP Right Grant
- 2018-08-10 ZA ZA201805302A patent/ZA201805302B/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
JP7479521B2 (ja) | 2020-06-24 | 2024-05-08 | エンテロバイオーム インコーポレイテッド | 新規なフィーカリバクテリウムプラウスニッツィイeb-fpdk9菌株およびその用途 |
KR102245415B1 (ko) * | 2020-12-14 | 2021-04-29 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주 배양 배지 조성물 |
WO2022131401A1 (ko) * | 2020-12-14 | 2022-06-23 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주 배양 배지 조성물 |
Also Published As
Publication number | Publication date |
---|---|
EP3407902B1 (fr) | 2020-07-15 |
LT3407902T (lt) | 2020-12-28 |
HUE050810T2 (hu) | 2021-01-28 |
ES2820338T3 (es) | 2021-04-20 |
AU2017211244A1 (en) | 2018-08-09 |
ZA201805302B (en) | 2019-10-30 |
JP6935632B2 (ja) | 2021-09-15 |
BR112018015121A2 (pt) | 2018-12-11 |
US10918678B2 (en) | 2021-02-16 |
EP3407902A1 (fr) | 2018-12-05 |
US20190030089A1 (en) | 2019-01-31 |
PT3407902T (pt) | 2020-09-03 |
CA3012214A1 (fr) | 2017-08-03 |
CN109310714A (zh) | 2019-02-05 |
AU2017211244B2 (en) | 2019-05-16 |
PL3407902T3 (pl) | 2021-04-06 |
IL260752B (en) | 2021-02-28 |
NZ744528A (en) | 2020-02-28 |
FR3046934A1 (fr) | 2017-07-28 |
FR3046934B1 (fr) | 2018-01-26 |
WO2017129515A1 (fr) | 2017-08-03 |
SG11201806361PA (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6935632B2 (ja) | 胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィcncm i−4573株 | |
EP2528610B1 (en) | Probiotic composition for use in the treatment of bowel inflammation | |
JP5868843B2 (ja) | 乳酸菌含有製剤 | |
JP2022525058A (ja) | 慢性炎症性疾患および/または炎症性消化器疾患および/または癌の予防および/または治療のためのクリステンセネラ科細菌 | |
US10420807B2 (en) | Lactobacillus salivarius for the treatment of mastitis | |
CN111676171B (zh) | 用于婴儿过度啼哭的益生菌 | |
US20220339207A1 (en) | Faecalibacterium prausnitzii and christensenella bacterial strains for the treatment and prevention of bowel inflammation | |
ES2553177T3 (es) | Cepas de Lactobacillus plantarum como probióticos con efecto inmunomodulador especifico | |
JP2021501586A (ja) | 新規な乳酸菌およびその使用 | |
CN111479927A (zh) | 丝氨酸蛋白酶抑制剂生产 | |
TW201636035A (zh) | 新穎副乾酪乳桿菌副乾酪亞種k66 | |
JP2022155522A (ja) | 免疫機能低下抑制剤及び免疫機能の低下抑制方法 | |
JP7225364B1 (ja) | 乳酸菌 | |
JP7492584B2 (ja) | ビフィドバクテリウム・ラクティスbl-99の腸管炎症の抑制における新規な用途 | |
Smoak | The effects of kefir and exercise on immune function and gut health | |
JP2023502708A (ja) | ビフィドバクテリウム・ラクティスbl-99の腸管炎症の抑制における新規な用途 | |
WO2021252632A2 (en) | Physiologically acceptable compositions containing microorganisms or microbial products | |
JP2022552721A (ja) | ビフィドバクテリウム・ビフィダムを含む免疫力増強または改善用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210702 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210729 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6935632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |